Showing results (11-20 of 724) with videos related to

Sort By:
Pageof 73
Haematologica|January 25, 2012
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapyNaveen Pemmaraju, Hagop Kantarjian, Jianqin Shan, et al.
Cancer|September 7, 2006
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemiaAlfonso Quintas-Cardama, Hagop Kantarjian, Susan O'Brien, et al.
Blood|August 2, 2011
The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitorsElias Jabbour, Hagop Kantarjian, Susan O'Brien, et al.
Blood|August 18, 2011
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignanciesDushyant Verma, Hagop Kantarjian, Sara S Strom, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 12, 2011
The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?Jorge Cortes, Alfonso Quintas-Cardama, Elias Jabbour, et al.
Leukemia Research|July 30, 2013
Modest activity of pomalidomide in patients with myelofibrosis and significant anemiaNaval Daver, Aditi Shastri, Tapan Kadia, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 25, 2013
Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trialsMusa Yilmaz, Hagop Kantarjian, Elias Jabbour, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2013
Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemiaAlireza Eghtedar, Hagop Kantarjian, Elias Jabbour, et al.
Haematologica|July 2, 2013
Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 monthsAziz Nazha, Hagop Kantarjian, Preetesh Jain, et al.
Blood|December 2, 2004
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemiaAlfonso Quintas-Cardama, Hagop Kantarjian, Moshe Talpaz, et al.
Pageof 73